Related Experiment Video

Updated: Sep 27, 2026

Recapitulation of an Ion Channel IV Curve Using Frequency Components
10:14

Recapitulation of an Ion Channel IV Curve Using Frequency Components

Published on: February 8, 2011

K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation

Colleen E Clancy1, Junko Kurokawa, Michihiro Tateyama

  • 1Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA. cc2114@columbia.edu

Annual Review of Pharmacology and Toxicology
|January 24, 2003
PubMed

Insights

Certain medications can cause dangerous heart rhythm disturbances by affecting potassium (K+) channels. Understanding drug interactions with these channels is crucial for preventing cardiac arrhythmias.

Area of Science:

  • Pharmacology
  • Cardiology
  • Molecular Biology

Background:

  • Non-cardiac medications can increase arrhythmia risk in susceptible patients.
  • Underlying genetic or structural factors can predispose individuals to drug-induced arrhythmias.
  • Several drug classes reduce repolarizing potassium (K+) currents, prolonging the QT interval.

Purpose of the Study:

  • To explore the mechanisms by which drugs disrupt cellular repolarization.
  • To understand the structural basis of potassium (K+) channel blockade.
  • To investigate the rate-dependent effects of drugs on cellular electrophysiology.

Main Methods:

  • Analysis of drug effects on cellular repolarization.
  • Investigation of potassium (K+) channel kinetics.
  • Electrocardiogram (ECG) analysis to assess QT interval prolongation.

Main Results:

  • Drug-induced blockade of repolarizing K+ currents identified as a key mechanism.
  • QT interval prolongation on ECG linked to increased arrhythmia susceptibility.
  • Structural determinants of K+ channel blockade are critical for understanding drug effects.

Conclusions:

  • Drug-induced disruption of cardiac repolarization is a significant cause of arrhythmias.
  • Understanding K+ channel interactions is vital for predicting and preventing adverse cardiac events.
  • Pharmacological interventions require careful consideration of potential proarrhythmic effects.

More Related Videos

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...